Get started
Ocugen, Inc.Ocugen, Inc.Ocugen, Inc.

Ocugen, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

OCGN trade ideas

Correction DueHaving Ocugen shorted has been one of my finest deals deals this year. I was lucky enough to stay short until now. But now I think that it's time for a correction. Not long ago there was a lot of buying phantasy among analysts and dealers. They have been disappointed. What is the situation now? I think that the market is almost clean now. Disappointed traders have sold or were stopped out. Many of those who had bought after the gap on March 20th shall have sold as well as there hopes have not come true and may have vanished after a double top. To avoid loss even the latest may have sold today in fear that the March window might to be shut. Remain those who have bought in January and February. They have made good profit. But due to the heavy fluctuations in February and the double top this month many of them shall have taken profit over time not willing ti lose the good profit. Due to the pressure this month the SEC has forbidden short selling of the stock, i.e. there shall not be many short position that may have to be covered. That is why I think that the market is almost balanced now and open for fresh ideas. SEC's ban of short selling is still valid and 1.28-1.35 is a resistance zone strong enough to halt the fall here having been the top on February 20th after the begin of the rise an then having been the bottom of the trading range before April 8th when markets became disappointed and fell. If this zone will hold tomorrow we may see a new buying wave. Option traders may be willing to sell puts below the open window.
NASDAQ:OCGNLong
by motleifaul
Bearish StartThe previous week could not reach the high of the week before. This was a hint that the bullish momentum is slowing down. The price reaction this week has confirmed this bias as the attempt to reached this high again has been sold immediately. This high seems to become an important resistance zone as it was a support zone for half a year from March to September 2022 and even a several times tested support/resistance zone for 2 years from December 2020 until November 2022. I see good chances therefor that this will defend its importance this time again.
NASDAQ:OCGNShort
by motleifaul
2
OCGN pumps on dismissal of investor lawsuit LONGOCGN has been a great swing trade after buying bad news. The good news has replaced the bad. Earnings are in three days. Price well below ATH. November earnings were a beat meaning this risky Med Tech penny stock had a lower cash burn than projected. Now legal costs will disappear. Going long with a decent position expecting a better earnings. In law, the Latin phrase res ipsa loquitur is sometimes used. Here it aptly applies to Ocugen.
NASDAQ:OCGNLong
by AwesomeAvani
1
Trading Idea - #OcugenMy trading idea for - #Ocugen - BUY Entry: 0.95 USD Target: 8.00 USD (+720% profit) Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA. Institutional Trading of Ocugen A number of large investors have recently added their stakes in OCGN. JPMorgan Chase & Co. increased its holdings in Ocugen by 20.9% during the first quarter. JPMorgan Chase & Co. now owns 4,015,742 shares of the company's stock worth $13,251,000 after buying an additional 693,786 shares during the last quarter. Raymond James Financial Services Advisors Inc. purchased a new stake in Ocugen during the first quarter worth about $47,000. Cetera Investment Advisers purchased a new stake in Ocugen during the first quarter worth about $50,000. Vanguard Group Inc. increased its holdings in Ocugen by 2.8% during the first quarter. Vanguard Group Inc. now owns 10,906,557 shares of the company's stock worth $35,991,000 after buying an additional 301,063 shares during the last quarter. Finally, Mackenzie Financial Corp bought a new position in Ocugen during the first quarter worth about $34,000. Hedge funds and other institutional investors own 21.50% of the company's stock. Ocugen Price Target Raised to $7.00/Share From $5.00 by HC Wainwright & Co.
NASDAQ:OCGNLong
by Traderherz-Analytics
2
$OCGN Ocugen Inc Long term PTs 16 - 21 - 180 and higherNASDAQ:OCGN Ocugen Inc Long term PTs 16 - 21 - 180 and higher Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
NASDAQ:OCGNLong
by BADQOMOCAWGOWLD
2
OCUGENThe wyckoff method is a very accurate method, There are many variations and purposes--soley to liquidate others or take shares from retail or weak hands, To sell of shares to FOMO traders or breakout traders. Liquidating Other institutions or create misleading Bullish signals and prices to entice investors etc, etc. the real skill is identifying the purpose of price movement, its likely targets of short term liquidity, and long term goals in correspondence to News.
NASDAQ:OCGNShort
by Integrity_Investments
5
OCGN Earnings Tomorrow! $15 Strike Price calls! WOWOcugen is a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines. They announced yesterday that it will host a conference call to provide a business update and discuss its first quarter 2022 financial results tomorrow, May 6, before the market opens. As soon as i saw the news, there were also 764 calls with a $15 strike price expiring jan 20 in the options chain. they paid a 11.5k premium paid for the calls. Considering that the price is 2.25, such an impressive out of the money bunch of calls made me think it was an insider information about something that could be released tomorrow. On 2/28/2022 S. Ramakanth from HC Wainwright gave a Buy rating for OCGN and a price target of $8.00, while Robert LeBoyer from Noble Financialhas a $15.00 price target. I`m extremely bullish on OCGN earnings tomorrow. Looking forward to read your opinion about it.
NASDAQ:OCGNLong
by TopgOptions
5
Ocugen ocgn Strong candles Big target 10.28hi all bro... OCUGEN firts target. 5.05 second 5.87 . and 6.10 big target:10.28 *****important- ***** thin line above price is the first target. thin line below price is support.. stop point. Fibonacci correction between the highest price and lowest fiat in the chart area are thick lines.. thick lines are hard support and hard resistances.. main target in fallen assets is the green line . decline in peak assets main target green line ********** thnks goodluck.. always stoploss ..
NASDAQ:OCGN
by Takaro
1